GW Pharmaceuticals PLC- (NASDAQ:GWPH) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.
A number of other analysts also recently weighed in on GWPH. Cowen reiterated an “outperform” rating and set a $165.00 price target on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. ValuEngine downgraded GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Leerink Swann reiterated an “outperform” rating and set a $153.00 price target (down from $160.00) on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $208.00 price target on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Finally, Goldman Sachs Group reissued a “neutral” rating and set a $124.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $148.78.
Shares of GW Pharmaceuticals PLC- (GWPH) opened at $134.61 on Friday. The company has a quick ratio of 7.47, a current ratio of 7.59 and a debt-to-equity ratio of 0.02. GW Pharmaceuticals PLC- has a 1-year low of $92.65 and a 1-year high of $136.95.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.